• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

DionyMed Announces Close of Acquisition with Innovative Industrial Properties for MMAC’s 1.83 Acre Los Angeles Campus

Share:

July 30, 2019

Toronto, Ontario, July 24, 2019 – DionyMed Brands Inc. (“DionyMed” or “Company”) (CSE: DYME) (OTCQB: DYMEF), a multi-state cannabis brands platform, today confirmed the official close of its previously announced acquisition of select assets from MM Esperanza 2 LLC, doing business as “MMAC,” and MMAC’s 1.83 acre Los Angeles cannabis campus, including retail, distribution, manufacturing and cultivation licenses, for the purchase price of US$13,067,000 in cash and US$6 million in DionyMed Series A Multiple Voting Shares to MMAC.
In conjunction with the close of the MMAC transaction, DionyMed has completed its sale-leaseback agreement with Innovative Industrial Properties, Inc. (NYSE: IIPR, “IIPR”), to purchase the Los Angeles cannabis campus for US$13 million and to enter into a long-term lease back of 15 years with two optional 5-year extensions. IIPR is also providing DionyMed up to US$2 million of capital to make improvements at the property.
The Los Angeles cannabis campus provides DionyMed:

  • A market leading, Southern California direct-to-consumer fulfillment center capable of supporting up to 600 cannabis delivery drivers
  • A dispensary storefront, distribution facility and manufacturing hub
  •  Premium indoor cultivation
  •  All property, leaseholds, equipment and licenses

DionyMed paid MMAC US$13,067,000 in cash and issued 55,374 (US$6 million) in DionyMed Series A Multiple Voting Shares. The shares issued to MMAC will be subject to a 120-day holding period and DionyMed has the right, but not the obligation, to repurchase the shares over the next 12 months for a 10% premium over the share price at closing of the transaction with MMAC.
Edward Fields, CEO of DionyMed, commented, “This acquisition strategically positions DionyMed as a leader in California’s cannabis market. By incorporating MMAC’s Southern California direct-to-consumer fulfillment center, distribution facility, manufacturing hub, cultivation facility and dispensary storefront, with our existing operational base in Northern California, DionyMed is positioned for long-term growth to serve the largest cannabis market in the country.”
To be added to the DionyMed e-mail distribution list, please e-mail DionyMed@kcsa.com with DionyMed in the subject line.

Date: July 30, 2019

Source: DionyMed

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Qiagen Fully Acquires Neumodx Molecular, Inc., Rounding Out Portfolio of PCR-Based Diagnostic Automation SystemsQiagen Fully Acquires Neumodx Molecular, Inc., Rounding Out Portfolio of PCR-Based Diagnostic Automation Systems
  • Mayo Clinic Launches Vocal Biomarker Study for Pulmonary Hypertension DetectionMayo Clinic Launches Vocal Biomarker Study for Pulmonary Hypertension Detection
  • STERIS Announces Definitive Agreement to Acquire Cantel MedicalSTERIS Announces Definitive Agreement to Acquire Cantel Medical
  • Ocbc Launches Healthcare App with Over 100 Doctors, Flat Consultation FeesOcbc Launches Healthcare App with Over 100 Doctors, Flat Consultation Fees
  • Venus Medtech Announces Agreement to Acquire Keystone Heart, LTDVenus Medtech Announces Agreement to Acquire Keystone Heart, LTD
  • Haemonetics To Transfer Union, South Carolina, Manufacturing Facility To CSL Plasma Inc.Haemonetics To Transfer Union, South Carolina, Manufacturing Facility To CSL Plasma Inc.
  • AiCure Raises $24.5 Million Series C Round to Broaden Its Strategic Value for Life SciencesAiCure Raises $24.5 Million Series C Round to Broaden Its Strategic Value for Life Sciences
  • Chimerix Acquires Oncoceutics to Expand Pipeline with Late-Stage Oncology ProgramChimerix Acquires Oncoceutics to Expand Pipeline with Late-Stage Oncology Program

Trending This Week

  • Bronchiolitis Drugs Market Expected to Witness High Growth Over the Forecast to 2027
  • Blood Bags Market Size Key Opportunity, Application and Forecast to 2027
  • Aesthetic Devices Market 2020 Industry Trends, Growth, Analysis, Opportunities and Overview
  • Pharmaceutical Packaging Market Size, Industry Demand, Regional Analysis & Insights 2027
  • Akerna Closes Acquisition of Viridian Sciences
  • Cryoport Acquires Temperature-Controlled Logistics Provider in Australia

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications